

Product datasheet for TL302717V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

P2Y2 (P2RY2) Human shRNA Lentiviral Particle (Locus ID 5029)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: P2Y2 (P2RY2) Human shRNA Lentiviral Particle (Locus ID 5029)

Locus ID: 5029

Synonyms: HP2U; P2RU1; P2U; P2U1; P2UR; P2Y2; P2Y2R

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: P2RY2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 002564, NM 176071, NM 176072, NM 002564.1, NM 002564.2, NM 176071.1,

NM 176071.2, NM 176072.1, NM 176072.2, BC012104, BC028135, NM 176071.3,

NM 176072.3, NM 002564.4

UniProt ID: P41231

shRNA Design:

Summary: The product of this gene belongs to the family of P2 receptors, which is activated by

extracellular nucleotides and subdivided into P2X ligand-gated ion channels and P2Y G-protein coupled receptors. This family has several receptor subtypes with different

pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor, found on many cell types, is activated by ATP and UTP and is reported to be overexpressed on some cancer cell types. It is involved in many cellular

functions, such as proliferation, apoptosis and inflammation. Three transcript variants

encoding the same protein have been identified for this gene. [provided by RefSeq, Mar 2013]

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com.

If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).